Breaking News, Financial News

Financial Report: Novo Nordisk

Revenues up 17% in first half

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novo Nordisk   1H Revenues: $6.2 billion (+17%) 1H Earnings: $1.7 billion (+22%) Comments: Modern insulin sales increased 20% to $2.8 billion, with sales of Victoza up 82% to $717 million. Biopharmaceutical segment sales were $1.4 billion, up 6%. Sales in North America increased by 29%. International sales increased 19%....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters